Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Tumor type

Melanoma

OncoTree code MEL · 7 articles

Clinical · Molecular biology

Integrated longitudinal analysis of ctDNA, radiologic response, and tumor volume reveals spatial and temporal heterogeneity in advanced melanoma

Heidrich I, Streckenbach A, Rautmann C, et al.

Journal of translational medicine

This study longitudinally analyzed circulating tumor DNA (ctDNA) in 42 patients with advanced melanoma treated with immune checkpoint inhibitors. ctDNA levels significantly correlated with radiological response according to RECIST 1.1 and total tumor volume, especially when measurements were temporally aligned. Although the discriminative performance for identifying progression was moderate, higher ctDNA thresholds demonstrated better specificity. The study also revealed marked heterogeneity in ctDNA shedding across metastatic sites, highlighting its potential as a complementary biomarker for disease monitoring.

Clinical · Molecular biology

Exploring the Role of TERT Promoter Mutations in Advanced Melanoma Treated With BRAF/MEK Inhibitors or Immune Checkpoint Inhibitors

Marchese PV, Zannini I, DE Biase D, et al.

Anticancer research

This retrospective single-center study investigated the role of TERT promoter mutations as a biomarker to guide treatment in advanced melanoma, particularly in BRAF V600 mutant patients. TERT mutations were detected in 73% of 159 patients and frequently co-occurred with BRAF V600 mutations. While TERT status was not an independent prognostic factor, exploratory analyses suggested a potential interaction with treatment type. Patients with BRAF/TERT co-mutations showed longer overall survival when treated with immune checkpoint inhibitors, whereas the opposite trend was observed for TERT wild-type patients receiving BRAF/MEK inhibitors. These preliminary findings warrant further validation in prospective studies.

Clinical · Molecular biology

Small-molecule RAS/RAF inhibitors target RAS-driven cancers via allosteric RAF disruption

Yoshikawa Y, Kubota H, Matsumoto S, et al.

Nature communications

This study focuses on developing novel inhibitors targeting the RAS/RAF pathway, a significant challenge in oncology given the frequency of RAS mutations and acquired resistance to existing treatments. Researchers identified small molecules that covalently bind to a distinct site within the RAS-binding domain of RAF, leading to allosteric disruption of its conformation. This mechanism prevents RAS/RAF interaction and downstream signaling. These compounds demonstrated preclinical antitumor efficacy against various cancers with KRAS, NRAS, and HRAS mutations, as well as wild-type RAS-driven cancers. They also suppressed tumor growth in BRAFV600E melanoma with acquired BRAF inhibitor resistance by preventing RAS signal reactivation.

Clinical · Molecular biology · Bioinfo & AI

Genomic Landscape of GNAQ and GNA11 Mutations in Metastatic Solid Tumors: A Real-World Data Analysis

Kwon M, Go Y, Shin JE, et al.

JCO precision oncology

This real-world study analyzed the genomic landscape of GNAQ and GNA11 mutations in 5,416 patients with metastatic solid tumors. It revealed that these mutations, while known in uveal melanoma, are also present in other cancers such as colorectal, melanoma, and gastric cancer. An immunogenic subgroup, characterized by non-hotspot mutations and high TMB or MSI, was identified and associated with potential benefit from immune checkpoint inhibitors. Canonical hotspot mutations, conversely, were predominant in TMB-low/MSS tumors. These findings highlight the importance of differentiating driver mutations from bystander mutations to guide therapeutic strategies.

Molecular biology · Bioinfo & AI

FFixR: a machine learning framework for accurate somatic mutation calling from FFPE RNA-seq data in cancer

Livne O, Yizhak K

Bioinformatics (Oxford, England)

A novel machine learning framework, FFixR, has been developed to address the challenges of somatic mutation detection from RNA sequencing (RNA-seq) data derived from formalin-fixed paraffin-embedded (FFPE) tissues. These tissues are prone to introducing artifacts that hinder accurate variant identification. FFixR effectively filters these artefactual mutations without requiring matched-normal samples. The tool demonstrated the ability to remove up to 98% of artifacts while maintaining good recall for true variants. This advancement enables more reliable analysis of archived FFPE samples, expanding their potential for research and clinical applications.

Clinical

Pathological Response and Toxicity of Neoadjuvant Immunotherapy in Advanced Melanoma

FitzGerald H, Carroll H, Ahmed Y

Irish medical journal

This retrospective study evaluated the efficacy and safety of neoadjuvant immunotherapy in 24 patients with locally advanced resectable melanoma. Treatment primarily involved pembrolizumab monotherapy or a combination of ipilimumab and nivolumab. A pathological complete response (pCR) rate of 16.7% and a pathological partial response (pPR) rate of 33.3% were observed. NRAS codon 61 mutations were present in 42% of patients, with 50% of these achieving a pPR. Toxicity, particularly colitis with combination therapy, represented a significant clinical challenge.

Clinical · Molecular biology

The impact of next generation sequencing studies on the diagnosis of BAP1 inactivated melanocytic tumors

Braat J, Trichy NS, Holic LJ, et al.

Human pathology

This study investigates the impact of next-generation sequencing (NGS) on the diagnosis of BAP1 inactivated melanocytic tumors (BIMTs), which often exhibit significant morphological atypia, complicating their classification. A survey among dermatopathologists revealed that incorporating NGS results significantly improved diagnostic accuracy and interobserver agreement. Specific genomic aberrations, including pathogenic variants in TERT-p, CDKN2A, PTEN, and MYC amplification, were found exclusively in malignant cases. These findings suggest that NGS could refine melanoma diagnosis, which is critical for guiding access to effective therapies.